569 related articles for article (PubMed ID: 20675343)
61. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma.
Szafranska AE; Davison TS; John J; Cannon T; Sipos B; Maghnouj A; Labourier E; Hahn SA
Oncogene; 2007 Jun; 26(30):4442-52. PubMed ID: 17237814
[TBL] [Abstract][Full Text] [Related]
62. miR-429 determines poor outcome and inhibits pancreatic ductal adenocarcinoma growth by targeting TBK1.
Song B; Zheng K; Ma H; Liu A; Jing W; Shao C; Li G; Jin G
Cell Physiol Biochem; 2015; 35(5):1846-56. PubMed ID: 25833382
[TBL] [Abstract][Full Text] [Related]
63. miR-200c inhibits breast cancer proliferation by targeting KRAS.
Song C; Liu LZ; Pei XQ; Liu X; Yang L; Ye F; Xie X; Chen J; Tang H; Xie X
Oncotarget; 2015 Oct; 6(33):34968-78. PubMed ID: 26392416
[TBL] [Abstract][Full Text] [Related]
64. XMD8-92 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanism.
Sureban SM; May R; Weygant N; Qu D; Chandrakesan P; Bannerman-Menson E; Ali N; Pantazis P; Westphalen CB; Wang TC; Houchen CW
Cancer Lett; 2014 Aug; 351(1):151-61. PubMed ID: 24880079
[TBL] [Abstract][Full Text] [Related]
65. miR-219-1-3p is a negative regulator of the mucin MUC4 expression and is a tumor suppressor in pancreatic cancer.
Lahdaoui F; Delpu Y; Vincent A; Renaud F; Messager M; Duchêne B; Leteurtre E; Mariette C; Torrisani J; Jonckheere N; Van Seuningen I
Oncogene; 2015 Feb; 34(6):780-8. PubMed ID: 24608432
[TBL] [Abstract][Full Text] [Related]
66. The Modulatory Role of MicroRNA-873 in the Progression of KRAS-Driven Cancers.
Mokhlis HA; Bayraktar R; Kabil NN; Caner A; Kahraman N; Rodriguez-Aguayo C; Zambalde EP; Sheng J; Karagoz K; Kanlikilicer P; Abdel Aziz AAH; Abdelghany TM; Ashour AA; Wong S; Gatza ML; Calin GA; Lopez-Berestein G; Ozpolat B
Mol Ther Nucleic Acids; 2019 Mar; 14():301-317. PubMed ID: 30654191
[TBL] [Abstract][Full Text] [Related]
67. KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma.
Ling J; Kang Y; Zhao R; Xia Q; Lee DF; Chang Z; Li J; Peng B; Fleming JB; Wang H; Liu J; Lemischka IR; Hung MC; Chiao PJ
Cancer Cell; 2012 Jan; 21(1):105-20. PubMed ID: 22264792
[TBL] [Abstract][Full Text] [Related]
68. KRAS/NF-κB/YY1/miR-489 Signaling Axis Controls Pancreatic Cancer Metastasis.
Yuan P; He XH; Rong YF; Cao J; Li Y; Hu YP; Liu Y; Li D; Lou W; Liu MF
Cancer Res; 2017 Jan; 77(1):100-111. PubMed ID: 27793842
[TBL] [Abstract][Full Text] [Related]
69. Impact of Oncogenic Targets Controlled by Tumor-Suppressive
Nepal P; Hozaka Y; Tanaka T; Wada M; Asai S; Minemura C; Idichi T; Arigami T; Kurahara H; Seki N; Ohtsuka T
Anticancer Res; 2021 Oct; 41(10):4821-4836. PubMed ID: 34593431
[TBL] [Abstract][Full Text] [Related]
70. miR-545 inhibited pancreatic ductal adenocarcinoma growth by targeting RIG-I.
Song B; Ji W; Guo S; Liu A; Jing W; Shao C; Li G; Jin G
FEBS Lett; 2014 Nov; 588(23):4375-81. PubMed ID: 25315416
[TBL] [Abstract][Full Text] [Related]
71. Constitutively active Akt1 cooperates with KRas(G12D) to accelerate in vivo pancreatic tumor onset and progression.
Albury TM; Pandey V; Gitto SB; Dominguez L; Spinel LP; Talarchek J; Klein-Szanto AJ; Testa JR; Altomare DA
Neoplasia; 2015 Feb; 17(2):175-82. PubMed ID: 25748236
[TBL] [Abstract][Full Text] [Related]
72. High expression of microRNA-4295 contributes to cell proliferation and invasion of pancreatic ductal adenocarcinoma by the down-regulation of Glypican-5.
Yuan Q; Zhang Y; Li J; Cao G; Yang W
Biochem Biophys Res Commun; 2018 Feb; 497(1):73-79. PubMed ID: 29407175
[TBL] [Abstract][Full Text] [Related]
73. CCAT2 is an oncogenic long non-coding RNA in pancreatic ductal adenocarcinoma.
Cai Y; Li X; Shen P; Zhang D
Biol Res; 2018 Jan; 51(1):1. PubMed ID: 29298720
[TBL] [Abstract][Full Text] [Related]
74. Mir34a constrains pancreatic carcinogenesis.
Hidalgo-Sastre A; Lubeseder-Martellato C; Engleitner T; Steiger K; Zhong S; Desztics J; Öllinger R; Rad R; Schmid RM; Hermeking H; Siveke JT; von Figura G
Sci Rep; 2020 Jun; 10(1):9654. PubMed ID: 32541781
[TBL] [Abstract][Full Text] [Related]
75. Differences in transcript levels of ABC transporters between pancreatic adenocarcinoma and nonneoplastic tissues.
Mohelnikova-Duchonova B; Brynychova V; Oliverius M; Honsova E; Kala Z; Muckova K; Soucek P
Pancreas; 2013 May; 42(4):707-16. PubMed ID: 23462326
[TBL] [Abstract][Full Text] [Related]
76. RAGE maintains high levels of NFκB and oncogenic Kras activity in pancreatic cancer.
Azizan N; Suter MA; Liu Y; Logsdon CD
Biochem Biophys Res Commun; 2017 Nov; 493(1):592-597. PubMed ID: 28867179
[TBL] [Abstract][Full Text] [Related]
77. Aurora A kinase and its activator TPX2 are potential therapeutic targets in KRAS-induced pancreatic cancer.
Gomes-Filho SM; Dos Santos EO; Bertoldi ERM; Scalabrini LC; Heidrich V; Dazzani B; Levantini E; Reis EM; Bassères DS
Cell Oncol (Dordr); 2020 Jun; 43(3):445-460. PubMed ID: 32193808
[TBL] [Abstract][Full Text] [Related]
78. Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal adenocarcinoma.
Lehnen NC; von Mässenhausen A; Kalthoff H; Zhou H; Glowka T; Schütte U; Höller T; Riesner K; Boehm D; Merkelbach-Bruse S; Kirfel J; Perner S; Gütgemann I
Histopathology; 2013 Aug; 63(2):157-66. PubMed ID: 23808822
[TBL] [Abstract][Full Text] [Related]
79. Docking Protein p130Cas Regulates Acinar to Ductal Metaplasia During Pancreatic Adenocarcinoma Development and Pancreatitis.
Costamagna A; Natalini D; Camacho Leal MDP; Simoni M; Gozzelino L; Cappello P; Novelli F; Ambrogio C; Defilippi P; Turco E; Giovannetti E; Hirsch E; Cabodi S; Martini M
Gastroenterology; 2022 Apr; 162(4):1242-1255.e11. PubMed ID: 34922945
[TBL] [Abstract][Full Text] [Related]
80. EZH2 coupled with HOTAIR to silence MicroRNA-34a by the induction of heterochromatin formation in human pancreatic ductal adenocarcinoma.
Li CH; Xiao Z; Tong JH; To KF; Fang X; Cheng AS; Chen Y
Int J Cancer; 2017 Jan; 140(1):120-129. PubMed ID: 27594424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
